Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration—Reply
JAMA · 2023
DOI: 10.1001/jama.2023.3497 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Nicolas Grillot und 1 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, Nantes, France. Hauptthemen laut MEDLINE: Analgesics, Opioid, Neuromuscular Blocking Agents, Rapid Sequence Induction and Intubation, Remifentanil. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
In Reply We appreciate these Letters about our study,1 which failed to demonstrate the noninferiority of remifentanil compared with neuromuscular blockers on rates of successful intubation on the first attempt without major complications in patients at risk of aspiration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Nantes Université, CHU Nantes, Nantes, France.
Zitieren
APA
Grillot, N., & Roquilly, A. (2023). Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration—Reply. JAMA. https://doi.org/10.1001/jama.2023.3497
Vancouver
Grillot N, Roquilly A. Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration—Reply. JAMA. 2023. doi:10.1001/jama.2023.3497
BibTeX
@article{Grillot2023,
author = {Grillot, Nicolas and Roquilly, Antoine},
title = {Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration—Reply},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.3497}
}
EUVIMED